Aptol Pharma ApS: Financial statements 2021
CVR: 39308967
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -2,464 the year before. Equity in the 2021 report amounted to DKK 50,000. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK 0
- Equity
- DKK 50,000
- Total Assets
- DKK 50,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 0 | 0 | 0 | 50 t. | - |
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
| 2018 | 0 | 89 t. | 129 t. | 50 t. | - |
Official annual report
Find more companies like Aptol Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Aptol Pharma ApS has published its annual report for 2020. Revenue came to DKK 0, and the net result was DKK -2,464.
About Aptol Pharma ApS
Aptol Pharma ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. According to the 2024 annual report, the company had an average of 1 employee. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.